Text Size

Analgesic Strategies in Newborns Receiving Prostaglandin Therapy

This study has been terminated.
(More important number of SAE in one arms)
Sponsor:
Information provided by:
Nantes University Hospital
ClinicalTrials.gov Identifier:
NCT00200590
First received: September 12, 2005
Last updated: April 18, 2008
Last verified: April 2008
History of Changes
  Purpose

This is a randomised trial comparing the efficacy of 3 different analgesic strategies in newborns on prostaglandin for ductus dependent congenital heart disease.


Condition Intervention
Pain
 Drug: acetaminophen and nalbuphine
Drug: acetaminophen and morphine
Drug: acetaminophen and reduced dosage of prostaglandin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Analgesic Strategies in Newborns Receiving Prostaglandin Therapy

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Nantes University Hospital:

Primary Outcome Measures:
  • Pain score [ Time Frame: before inclusion and at 8 hours (H8), H24, H48, H72 ]

Secondary Outcome Measures:
  • Incidence of apnea
  • Need for mechanical ventilation
  • Incidence of fever
  • Pattern of feeding (oral, nasogastric [NG] tubing, parenteral nutrition)

Estimated Enrollment: 30
Study Start Date: December 2003
Study Completion Date: July 2006
Primary Completion Date: July 2006 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   up to 28 Days
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Full-term newborn
  • Under one month of age
  • With ductus dependent congenital heart disease requiring prostaglandin infusion and elevated pain score

Exclusion Criteria:

  • Contraindication to either morphine, acetaminophen, or nalbuphine
  • Other painful condition
  • Poor neurological condition
  • Cardiac instability requiring urgent surgery
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00200590

Locations
France
Nantes University Hospital
Nantes, France, 44093
Sponsors and Collaborators
Nantes University Hospital
Investigators
Principal Investigator: Véronique Gournay, MD Nantes UH
  More Information

No publications provided

Responsible Party: Dr Véronique Gournay, CHU de Nantes
ClinicalTrials.gov Identifier: NCT00200590     History of Changes
Other Study ID Numbers: BRD/03/7-D
Study First Received: September 12, 2005
Last Updated: April 18, 2008
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Nantes University Hospital:
prostaglandin
analgesia
congenital
 heart
defect
induced

Additional relevant MeSH terms:
Acetaminophen
Analgesics
Morphine
Nalbuphine
Antipyretics
Physiological Effects of Drugs
Pharmacologic Actions
Analgesics, Non-Narcotic
 Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Analgesics, Opioid
Central Nervous System Depressants
Narcotics
Narcotic Antagonists

ClinicalTrials.gov processed this record on May 19, 2013